Affiliations 

  • 1 Department of Dermatology, Hospital Sultanah Aminah, Clinical School Johor Bahru, Monash University Malaysia, Johor Bahru, Malaysia
  • 2 Icahn School of Medicine at Mount Sinai, New York, New York, USA
  • 3 Department of Dermatology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia
  • 4 Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China
  • 5 Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
  • 6 Boehringer Ingelheim (China), Investment Co., Ltd., Shanghai, China
  • 7 Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • 8 Boehringer Ingelheim International GmbH, Biberach, Germany
  • 9 Service de Dermatologie, Assistance Publique - Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université Paris Cité, Paris, France
Dermatology, 2023;239(3):345-354.
PMID: 36796336 DOI: 10.1159/000529274

Abstract

BACKGROUND: Generalized pustular psoriasis (GPP) is a rare, neutrophilic skin disease that can become life-threatening if flares are untreated. There are limited data describing the characteristics and clinical course of GPP disease flares with current treatment options.

OBJECTIVE: The aim of the study was to describe the characteristics and outcomes of GPP flares using historical medical information from patients enrolled in the Effisayil™ 1 trial.

METHODS: Investigators collected retrospective medical data characterizing patients' GPP flares prior to clinical trial enrollment. Data on overall historical flares were collected, as well as information on patients' typical, most severe, and longest past flares. This included data on systemic symptoms, flare duration, treatment, hospitalization, and time to clearance of skin lesions.

RESULTS: In this cohort (N = 53), patients with GPP experienced a mean of 3.4 flares per year. Flares were painful, associated with systemic symptoms, and often triggered by stress, infections, or treatment withdrawal. Resolution of flares was longer than 3 weeks in 57.1%, 71.0%, and 85.7% of documented (or identified) typical, most severe, and longest flares, respectively. GPP flares led to patient hospitalization in 35.1%, 74.2%, and 64.3% of patients for their typical, most severe, and longest flares, respectively. For the majority of patients, pustules took up to 2 weeks to clear for a typical flare and 3-8 weeks to clear for the most severe and longest flares.

CONCLUSION: Our findings highlight that current treatment options are slow to control GPP flares and provide context for assessing the efficacy of new therapeutic strategies in patients with a GPP flare.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications